Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx Appoints Mardi C. Dier as Chief Financial Officer

GlobeNewswire September 2, 2020

Ultragenyx Expands Leadership Team and Appoints Ernie Meyer as Chief Human Resources Officer

GlobeNewswire September 1, 2020

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire August 4, 2020

Ultragenyx Reports Second Quarter 2020 Financial Results and Corporate Update

GlobeNewswire July 30, 2020

Ultragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate Update

GlobeNewswire July 24, 2020

Ultragenyx Announces U.S. Commercial Launch of Dojolvi(TM) (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders

GlobeNewswire July 22, 2020

Ultragenyx Announces U.S. FDA Approval of Dojolvi(TM) (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders

GlobeNewswire June 30, 2020

Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)

GlobeNewswire June 18, 2020

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire May 28, 2020

Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics

GlobeNewswire May 21, 2020

Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

GlobeNewswire May 15, 2020

Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency

GlobeNewswire May 13, 2020

Ultragenyx to Present at BofA Securities Global Health Care Conference

GlobeNewswire May 11, 2020

Ultragenyx Reports First Quarter 2020 Financial Results and Corporate Update

GlobeNewswire May 6, 2020

GeneTx and Ultragenyx Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome

GlobeNewswire May 4, 2020

Ultragenyx to Host Conference Call for First Quarter 2020 Financial Results and Corporate Update

GlobeNewswire April 30, 2020

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2020 Virtual Annual Meeting

GlobeNewswire April 28, 2020

Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology

GlobeNewswire March 31, 2020

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder

GlobeNewswire March 31, 2020

GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome

GlobeNewswire March 16, 2020